While patients with NSCLC will undergo NGS profiling for comprehensive biomarker identification, the proposed model offers a targeted pre-screening mechanism to prioritize testing for ALK and ROS1 fusions. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.